Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates.
Kemshead
J T
JT
Imperial Cancer Research Fund Paediatric and Neuro-Oncology Group, Frenchay Hospital, Bristol, UK.
Hopkins
K I
KI
Chandler
C L
CL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001099:Arachnoid / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007278:Injections, Spinal; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000532:radiotherapy*; D008657:Metabolic Clearance Rate; D009360:Neoplastic Cells, Circulating / Q000528:radiation effects; D010841:Pia Mater / Q000528:radiation effects*; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage
D000911:Antibodies, Monoclonal; D018796:Immunoconjugates; D007457:Iodine Radioisotopes